Drugs

Meet 2014's Blockbuster Drugs


Meet 2014's Blockbuster Drugs

These five medicines are predicted to be big moneymakers:

GA101
Roche’s (RHHBY) experimental leukemia drug beat the company’s top seller, Rituxan, in a trial that may position it as the older treatment’s heir. Annual revenue is forecast to reach $1.4 billion in 2018, based on a Bloomberg survey of six analysts.

LEMTRADA
Sanofi (SNY) gained access to this antibody-based therapy for multiple sclerosis through its purchase of Genzyme in 2011. The market for MS drugs is forecast to grow from $13.8 billion to $19.6 billion by 2022, according to Credit Suisse (CS).

IBRUTINIB
Johnson & Johnson (JNJ) and Pharmacyclics’ (PCYC) treatment for two types of blood cancer is poised to hit the market earlier than anticipated, after the U.S. Food and Drug Administration designated it a breakthrough therapy. Considered one of the most promising late-stage cancer drugs in the pipeline, ibrutinib has the potential to earn $5 billion a year.

ANORO
GlaxoSmithKline (GSK) and Theravance (THRX) are collaborating on this treatment for emphysema and chronic bronchitis, which may get final FDA approval as early as December. Anoro is expected to generate $1.2 billion in sales in 2018, according to Bloomberg consensus estimates.

SOFOSBUVIR
The race is on for an all-oral combination therapy to treat hepatitis C, a disease that attacks the liver, and Gilead Sciences’ (GILD) once-daily pill is in the lead. Analysts expect sofosbuvir to generate $6 billion in sales a year.


American Apparel's Future
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • RHHBY
    (Roche Holding AG)
    • $36.97 USD
    • 0.11
    • 0.3%
  • SNY
    (Sanofi)
    • $51.63 USD
    • -0.04
    • -0.08%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus